I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging (MRI) images along with tissue and blood samples) are predictors of treatment success.

Trial Details

NCT ID
NCT01042379
Phase
PHASE2
Sponsor
QuantumLeap Healthcare Collaborative
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • Standard Therapy
  • AMG 386 with or without Trastuzumab
  • AMG 479 (Ganitumab) plus Metformin
  • MK-2206 with or without Trastuzumab
  • AMG 386 and Trastuzumab
  • T-DM1 and Pertuzumab
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • Tucson, Arizona, United States|32.22174,-110.92648
  • Davis, California, United States|38.54491,-121.74052
  • Duarte, California, United States|34.13945,-117.97729

Key Eligibility Criteria

  • Histologically confirmed invasive cancer of the breast
  • Clinically or radiologically measureable disease in the breast after diagnostic biopsy, defined as longest diameter greater than or equal to 25 mm …
  • No prior cytotoxic regimens are allowed for this malignancy. Patients may not have had prior chemotherapy or prior radiation therapy to the ipsilat…
  • Age ≥18 years

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →